Related Experiment Video
Updated: Feb 20, 2026
Author Spotlight: High-Throughput Image-Based Quantification of Mitochondrial DNA Synthesis and Distribution
Published on: May 5, 2023
Construction of a Bcl-2-shRNA expression vector and its effect on the mitochondrial apoptosis pathway in SW982 cells
Weidong Zhang1, Xinjie Xue1, Teng Fu2
1Guangming Hospital of Traditional Chinese Medicine, Shanghai 201300, P.R. China.
Abstract:
Apoptosis is considered to serve an important role in the pathogenesis of rheumatoid arthritis. The aim of the present study was to construct Bcl-2-short hairpin (sh)RNA expression vectors and transfect them into human synovial sarcoma SW982 cells, in order to screen for an effective interference sequence and analyze the effects of this interference on the expression levels of Bcl-2 and other molecules associated with the mitochondrial apoptosis pathway. Three different shRNAs (Bcl-2-sh1, 2 and 3) were designed according to the human Bcl-2 mRNA target sequence and were transformed into competent DH5α Escherichia coli cells following the construction of an expression vector, which was then transfected into SW982 cells. SW982 cells were grouped into a control group (transfected with a negative control shRNA), and Bcl-2-sh1, Bcl-2-sh2 and Bcl-2-sh3 groups (transfected with Bcl-2-sh1, 2 and 3, respectively). The expression levels of Bcl-2 mRNA were detected using reverse transcription-quantitative PCR (RT-qPCR). Bcl-2-sh1 was identified as the most effective shRNA sequence for interference, and was used for subsequent experiments. The mRNA and protein expression levels of Bcl-2, Bax, CytC and Caspase-3 were detected in SW982 cells by RT-qPCR and western blotting at various time-points (48 and 72 h) following transfection with Bcl-2-sh1, in order to observe the effectiveness of this interference. Compared with the control group, the expression levels of Bcl-2 were decreased, while those of Bax, CytC and Caspase-3 were increased in Bcl-2-sh1-transfected cells (P<0.01). The interference effect was greater at 48 h than at 72 h. In summary, an effective shRNA sequence (Bcl-2-sh1) targeting the Bcl-2 gene was identified from three candidates, and was demonstrated to significantly interfere with the expression of Bcl-2, Bax, CytC and Caspase-3 when transfected into SW982 cells. The interference effect of Bcl-2-sh1 was more pronounced at 48 h than at 72 h post-transfection.
Insights
Researchers identified an effective short hairpin RNA (shRNA) sequence, Bcl-2-sh1, to inhibit Bcl-2 expression in human synovial sarcoma cells. This interference impacts mitochondrial apoptosis pathway molecules, offering potential therapeutic insights for rheumatoid arthritis.
Area of Science:
- Molecular Biology
- Cell Biology
- Pathogenesis Research
Background:
- Apoptosis plays a critical role in rheumatoid arthritis pathogenesis.
- Understanding the molecular mechanisms of apoptosis is crucial for developing targeted therapies.
Purpose of the Study:
- To construct and evaluate Bcl-2-short hairpin (sh)RNA expression vectors for gene silencing.
- To analyze the impact of Bcl-2 interference on the mitochondrial apoptosis pathway in SW982 cells.
Main Methods:
- Designed and synthesized three distinct Bcl-2 shRNA sequences (Bcl-2-sh1, 2, 3).
- Transfected SW982 cells with shRNA vectors and a negative control.
- Quantified mRNA and protein expression of Bcl-2, Bax, CytC, and Caspase-3 using RT-qPCR and Western blotting.
Main Results:
- Bcl-2-sh1 demonstrated the most effective interference with Bcl-2 expression.
- Transfection with Bcl-2-sh1 significantly decreased Bcl-2 levels.
- Bcl-2-sh1 transfection upregulated Bax, CytC, and Caspase-3 expression, indicating apoptosis induction.
- The interference effect was more pronounced at 48 hours post-transfection compared to 72 hours.
Conclusions:
- An effective shRNA (Bcl-2-sh1) targeting Bcl-2 was identified.
- Bcl-2-sh1 successfully interfered with Bcl-2 expression and modulated key mitochondrial apoptosis pathway molecules in SW982 cells.
- The findings suggest Bcl-2 targeting as a potential strategy in managing diseases involving aberrant apoptosis, such as rheumatoid arthritis.
